US FDA approves expanded use for Dovato (dolutegravir/lamivudine) as a complete regimen for adults with HIV who are virologically suppressed on another regimen
In the US, Dovato is now approved for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a stable regimen with no history of treatment failure and no known resistance to its individual components.
Source:
Biospace Inc.